Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
You may also be interested in...
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.